N/A
Completed N=150
Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients
Source: ClinicalTrials.gov NCT02401867 ↗Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants — p=.29
Summary
The purpose of this study is to assess the acceptability and effectiveness of utilizing vaginal self-swabs for HPV DNA testing as compared to provider-collected cervical swabs for HPV, as well as to investigate the prevalence of other Sexually Transmitted Infections (STIs) among sexually active female-to-male (FTM) transgender adults.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults |
15; 2; 6; 108 | .29 |
Eligibility Criteria
Inclusion Criteria
- Age 21-64
- Assigned a female sex at birth and now self-identifies as a man, trans masculine, trans man, FTM, transgender, genderqueer/non-binary, transsexual, male, and/or another diverse transgender identity or expression
- Have a cervix
- Sexually active in the past 36 months (with sexual partner(s) of any gender)
- Able to speak and understand English
- Willing and able to provide informed consent
Exclusion Criteria
- Unable to provide informed consent due to severe mental or physical illness
- Substance intoxication at the time of interview
Data sourced from ClinicalTrials.gov (NCT02401867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.